Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,460JPY
20 Sep 2017
Change (% chg)

¥-6 (-0.38%)
Prev Close
¥1,466
Open
¥1,459
Day's High
¥1,466
Day's Low
¥1,455
Volume
7,961,900
Avg. Vol
7,546,668
52-wk High
¥1,688
52-wk Low
¥1,332

Latest Key Developments (Source: Significant Developments)

Amgen Astellas and Astellas announce submission of application for investigational osteoporosis medication romosozumab in Japan
Tuesday, 20 Dec 2016 12:17am EST 

Astellas Pharma Inc <4503.T>: Says Amgen Astellas BioPharma K.K. and Astellas Pharma Inc announced that Amgen Astellas submitted an application seeking marketing approval of romosozumab (AMG785) for the treatment of osteoporosis for those at high risk of fracture for review to the Ministry of Health, Labour and Welfare in Japan .Says Amgen Astellas and Astellas are co-developing romosozumab in Japan.  Full Article

Astellas says extends commitment with Canadian Urological Association
Friday, 18 Nov 2016 09:00am EST 

Astellas Pharma Inc <4503.T> :Astellas Pharma Canada says renewal of Canadian Urological Association Astellas Research Grant Program for an additional three years.  Full Article

Astellas Pharma files lawsuit against patent infringement of Myrbetriq® in U.S.
Thursday, 6 Oct 2016 09:27pm EDT 

Astellas Pharma Inc <4503.T>:Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas’ mirabegron (generic name) product sold under the trademark Myrbetriq® in the U.S..  Full Article

Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan
Wednesday, 28 Sep 2016 01:45am EDT 

Astellas Pharma Inc <4503.T>:Says the co received a marketing approval of Kiklin® Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan.  Full Article

Astellas Pharma to create companion diagnostic for acute Myeloid Leukemia treatment-Nikkei<4503.T>
Monday, 15 Aug 2016 03:39pm EDT 

Nikkei: Astellas Pharma to create with U.S. co so-called companion diagnostic for acute myeloid leukemia treatment the co has been working on-Nikkei . Astellas Pharma seeks to obtain approval in Japan, U.S. and elsewhere within three years-Nikkei .  Full Article

Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan
Tuesday, 9 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder .Says it has a license agreement with AstraZeneca UK Ltd. that provides the co exclusive rights to develop and commercialize extended-release tablets of quetiapine fumarate in Japan.  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 10:57am EDT 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

DigiTx Partners says raised about $10.5 mln in equity financing
Thursday, 4 Aug 2016 12:35pm EDT 

Digitx Partners Llc : Digitx Partners LLC says it raised about $10.5 mln in equity financing of the total offering amount of $21 mln - SEC .  Full Article

Astellas Pharma unit to sell Astellas Pharma Technologies to Avara
Thursday, 4 Aug 2016 02:00am EDT 

Astellas Pharma Inc <4503.T>: Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time) .Says transaction price is not disclosed.  Full Article

Astellas to transfer U.S. manufacturing unit to Avara
Wednesday, 3 Aug 2016 08:52pm EDT 

Astellas Pharma Inc <4503.T> : Astellas announces transfer of U.S. manufacturing subsidiary to Avara . Under terms of transaction, APT employees will remain employed at site .Astellas Pharma Technologies, Inc. will be renamed Avara Pharmaceutical Technologies, Inc.  Full Article

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I